Journal of Yeungnam Medical Science

Yeungnam University College of Medicine, Yeungnam University Institute Medical Science (영남대 의대 학술지 편집위원회)
권호 표지
DOI QR코드

DOI QR Code

Delayed treatment-free response after romiplostim discontinuation in pediatric chronic immune thrombocytopenia

  • Lim, Hyun Ji (Department of Pediatrics, Yeungnam University Hospital) ;
  • Lim, Young Tae (Department of Pediatrics, Yeungnam University Hospital) ;
  • Hah, Jeong Ok (Department of Pediatrics, Daegu Fatima Hospital) ;
  • Lee, Jae Min (Department of Pediatrics, Yeungnam University College of Medicine)
  • Received : 2020.06.18
  • Accepted : 2020.07.18
  • Published : 2021.04.30
Download PDF
⟨ Previous Next ⟩

Abstract

We report the case of a 16-month-old patient with chronic immune thrombocytopenia (ITP) patient who experienced delayed treatment-free response (TFR) after romiplostim treatment. He received intravenous immunoglobulin every month to maintain a platelet count above 20,000/µL for 2 years. Thereafter, he received rituximab and cyclosporine as second-line therapy, with no response, followed by romiplostim. After 4 weeks of treatment, the platelet count was maintained above 50,000/µL. Following 7 months of treatment, he discontinued romiplostim, and the platelet count decreased. His platelet counts remained above 50,000/µL, without any bleeding symptoms, 2 years after romiplostim discontinuation. This is the first report of TFR after romiplostim treatment in pediatric chronic ITP.

Keywords

Acknowledgement

This work was supported by 2019 Yeungnam University Research Grant.

References

  1. Kim JY. Diagnostic approach of childhood immune thrombocytopenia. Clin Pediatr Hematol Oncol 2018;25:10-6. https://doi.org/10.15264/cpho.2018.25.1.10
  2. Kim YK, Lee SS, Jeong SH, Ahn JS, Yang DH, Lee JJ, et al. Efficacy and safety of eltrombopag in adult refractory immune thrombocytopenia. Blood Res 2015;50:19-25. https://doi.org/10.5045/br.2015.50.1.19
  3. Neunert CE, Rose MJ. Romiplostim for the management of pediatric immune thrombocytopenia: drug development and current practice. Blood Adv 2019;3:1907-15. https://doi.org/10.1182/bloodadvances.2019000279
  4. Tarantino MD, Bussel JB, Blanchette VS, Despotovic J, Bennett C, Raj A, et al. Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study. Lancet 2016;388:45-54. https://doi.org/10.1016/S0140-6736(16)00279-8
  5. Franchini M, Veneri D, Lippi G. Thrombocytopenia and infections. Expert Rev Hematol 2017;10:99-106. https://doi.org/10.1080/17474086.2017.1271319
  6. Thota S, Kistangari G, Daw H, Spiro T. Immune thrombocytopenia in adults: an update. Cleve Clin J Med 2012;79:641-50. https://doi.org/10.3949/ccjm.79a.11027
  7. Kistangari G, McCrae KR. Immune thrombocytopenia. Hematol Oncol Clin North Am 2013;27:495-520. https://doi.org/10.1016/j.hoc.2013.03.001
  8. Kuter DJ, Bussel JB, Lyons RM, Pullarkat V, Gernsheimer TB, Senecal FM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet 2008;371:395-403. https://doi.org/10.1016/S0140-6736(08)60203-2
  9. Mathias SD, Li X, Eisen M, Carpenter N, Crosby RD, Blanchette VS. A phase 3, randomized, double-blind, placebo-controlled study to determine the effect of romiplostim on health-related quality of life in children with primary immune thrombocytopenia and associated burden in their parents. Pediatr Blood Cancer 2016;63:1232-7. https://doi.org/10.1002/pbc.25984
  10. Tarantino MD, Bussel JB, Blanchette VS, Beam D, Roy J, Despotovic J, et al. Long-term treatment with romiplostim and treatment-free platelet responses in children with chronic immune thrombocytopenia. Haematologica 2019;104:2283-91. https://doi.org/10.3324/haematol.2018.202283
  11. Lozano ML, Mingot-Castellano ME, Perera MM, Jarque I, Campos-Alvarez RM, Gonzalez-Lopez TJ, et al. Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia. Sci Rep 2019;9:16680. https://doi.org/10.1038/s41598-019-53209-y